15 Jul 2026 | Press release
Christof Ehrhart will leave position as Bosch’s Head of Communications at the end of the year
Find out more
15 Jul 2026 | Press release
11.01.2021
Press release
Business/economy
Bosch Hemoglobin Monitor: Early detection of anemia without blood tests
Bengaluru, India / Waiblingen, Germany – According to estimations by the WHO 1.6 billion people suffer from Anemia, a condition resulting from the reduced hemoglobin concentration in the blood. This has prompted the WHO to define the fight against anemia as one of its critical sustainable development goals for 2025. Bosch has developed a portable Hemoglobin Monitor Solution (HMS) especially for regions where routine access to medical care tends to be difficult. This HMS allows a large number of people to be screened for anemia rapidly, safely, using a non-invasive approach. The solution has been named a CES Innovation Award Honoree in the “Health and Wellness” category. “Bosch has developed the non-invasive Hemoglobin monitor as an innovative solution and as an alternative to traditional methods for the early detection of anemia. This should offer people better diagnosis options even in resource constrained conditions. The use of artificial intelligence is revolutionizing anemia management, specifically in point-of-care setups and closer to the patient”, explains Dattatri Salagame, President and Managing Director of Robert Bosch Engineering and Business Solutions Private Limited (RBEI). Bosch has developed the non-invasive Hemoglobin monitor as an innovative solution and as an alternative to traditional methods for the early detection of anemia. This should offer people better diagnosis options even in resource constrained conditions. The use of artificial intelligence is revolutionizing anemia management, specifically in point-of-care setups and closer to the patient....Dattatri Salagame, President and Managing Director of Robert Bosch Engineering and Business Solutions Private Limited (RBEI) Hemoglobin is a protein found in red blood cells and is responsible for carrying oxygen and carbon dioxide throughout the body. People with a low hemoglobin count may experience symptoms such as general fatigue, weakness, pale skin, and even serious illnesses. Anemia particularly affects women, even more so when they are pregnant, and also people suffering from malnutrition. In cancer patients undergoing chemotherapy or in palliative care, hemoglobin levels should be checked regularly. Hemoglobin results in 30 seconds using a non-invasive AI measurement The intelligent solution by Bosch is designed for use directly at the point-of-care and is completely pain-free with no need for a blood test, as the value is determined by a finger scanner using multi-wavelength spectrophotometry on the surface of the skin. The system uses an optical sensor to precisely and reliably measure the photoplethysmogram (PPG) signals. Photoplethysmography, or PPG, is an optical technique used to detect volumetric changes in blood in peripheral circulation. The device provides a reliable result within 30 seconds even for low hemoglobin concentrations. This is where machine learning comes in: the device’s algorithm monitors the wavelength of the light and uses 27 different characteristics to determine and classify the hemoglobin value. The algorithm has been trained with more than 10,000 anemia data points. These clinically collected data along with the corresponding ground truth data, are the basis for the machine learning algorithm. The more validated data sets are put into the continuously learning algorithm, the more precise the results will be. Lab-free results without risk of infection A laboratory analysis is not necessary and there is no risk of infection from contaminated needles. Participants receive their test results quickly at the point of care. The device is battery operated, does not need subsequent calibration, and is extremely easy to use. It is intended for use in outlying and remote regions by healthcare professionals. Location-based reporting ensures easy clinical traceability. Organizations that operate multiple devices can draw conclusions through heat maps about specific regions. Patient data remains anonymous. Market release in India is expected by mid-2021.
